share_log

Why Are Akebia Therapeutics Shares Falling Today?

Why Are Akebia Therapeutics Shares Falling Today?

為什麼木通治療公司的股票今天下跌？
Benzinga Real-time News ·  2022/05/16 14:16
  • Akebia Therapeutics Inc (NASDAQ:AKBA) and Otsuka Holdings (OTC: OTSKY) separately announced to call for licensing and co-development agreement for vadadustat.
  • Otsuka sent a written notice to Akebia on May 12 that the partnership had been terminated. 
  • Akebia said in an SEC filing filed Friday that the termination will go into effect in a year.
  • Related: FDA Places Partial Hold On Vadadustat Pediatric Studies, Akebia Cuts Over 40% Staff.
  • The deal was initially announced in 2016, offering $265 million in committed cash, including $125 million upfront, with another $35 million due in early 2017. 
  • The deal also gave Otsuka US co-commercialization rights for Akebia's drug, as it paid $105 million to help cover development costs and offered up to $765 million in milestones.
  • Otsuka said, "Otsuka and Akebia had been co-developing vadadustat for renal anemia. However, in March, Akebia received a Complete Response Letter from the FDA. As a result, Otsuka has decided to terminate its co-development of vadadustat and has notified Akebia of the termination of its global license agreements."
  • Akebia also said in an SEC filing that Otsuka terminated the deal for "alleged material breaches by the Company under the Otsuka U.S. Agreement," which could force the deal's end as early as June 12. 
  • Akebia further added that it disagrees and plans to dispute the allegations of "material breach."
  • Price Action: AKBA shares are down 16.6% at $0.37 during the market session on the last check Monday.
  • 木通治療公司(納斯達克：AKBA)和大冢控股(場外交易代碼：OTSKY)單獨宣佈呼籲簽署vadustat的許可和共同開發協議。
  • 大冢於5月12日向Akebia發出書面通知，稱合作關係已終止。
  • 木通在週五提交給美國證券交易委員會的一份文件中表示，終止將在一年內生效。
  • 相關： FDA部分暫停Vadadustat兒科研究，Akebia裁員40%以上.
  • 這筆交易最初是在2016年宣佈的，承諾提供2.65億美元的現金，其中包括1.25億美元的預付款，另有3500萬美元將於2017年初到期。
  • 這筆交易還讓大冢美國公司獲得了Akebia藥物的聯合商業化權利，因為它支付了1.05億美元來幫助支付開發成本，並提供了高達7.65億美元的里程碑。
  • 大冢説：“大冢和Akebia一直在共同開發治療腎性貧血的vadustat。然而，Akebia在3月份收到了FDA的完整回覆信。因此，大冢決定終止其共同開發的vadustat，並已通知Akebia終止其全球許可協議。”
  • Akebia還在一份美國證券交易委員會文件中表示，大冢終止了這筆交易，原因是“根據大冢美國協議，公司涉嫌存在重大違規行為”，這可能會迫使交易最早在6月12日結束。
  • Akebia進一步補充説，它不同意這一説法，並計劃駁斥有關“實質性違規”的指控。
  • 價格行動：週一收盤時，AKBA股價下跌16.6%，至0.37美元。
声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論